Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Nonsquamous Non-small Cell Lung Cancer × Pemetrexed × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 11 Lung Neoplasms 5 NSCLC 2 Mesothelioma 2 Recurrence 1 Nonsquamous Non-small Cell Lung Cancer 1 Non-squamous Non-small Cell Lung Cancer 1 Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

pembrolizumab 1 Pemetrexed 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡